Anti-LRP/LR Antibody W3 Hampers Peripheral PrPSc Propagation in Scrapie Infected Mice

References

• Aguzzi A, Weissmann C. Prion diseases. Haemophilia 1998; 4:619 - 627
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363 - 13383
   PubMed Web of Science ®Google Scholar
• Lasmézas CI, Weiss S. Cary JW, Linz JE, Bhatnagar D. Molecular Biology of Prion Diseases. Microbial Foodborne Diseases Mechanisms of Pathogenicity and Toxin Synthesis 2000; Lancaster (USA) Technomic Publishing CO., INC 495 - 537
   Google Scholar
• Weissmann C. The state of the prion. Nat Rev Microbiol 2004; 2:861 - 871
   PubMed Web of Science ®Google Scholar
• Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, Kretzschmar H. Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci USA 2004; 101:12207 - 12211
   PubMed Web of Science ®Google Scholar
• Weissmann C. Birth of a prion: Spontaneous generation revisited. Cell 2005; 122:165 - 168
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Heikenwalder M, Miele G. Progress and problems in the biology, diagnostics, and therapeutics of prion diseases. J Clin Invest 2004; 114:153 - 160
   PubMedGoogle Scholar
• Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I, Weiss S. Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther 2007; 5:613 - 630
   PubMed Web of Science ®Google Scholar
• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129:2241 - 2265
   PubMed Web of Science ®Google Scholar
• Vana K, Zuber C, Nikles D, Weiss S. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell Mol Neurobiol 2007; 27:107 - 128
   PubMed Web of Science ®Google Scholar
• Weissmann C, Aguzzi A. Approaches to therapy of prion diseases. Annu Rev Med 2005; 56:321 - 344
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80 - 83
   PubMed Web of Science ®Google Scholar
• Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE, Williamson RA, Burton DR, Pluckthun A. Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 2006; 363:75 - 97
   PubMed Web of Science ®Google Scholar
• Padiolleau-Lefevre S, Alexandrenne C, Dkhissi F, Clement G, Essono S, Blache C, Couraud JY, Wijkhuisen A, Boquet D. Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: Implications for therapeutic use in prion diseases. Mol Immunol 2007; 44:1898 - 1906
   Web of Science ®Google Scholar
• Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, Spinner DS, Carp RI, Meeker HC, Sadowski M, Wisniewski T. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 2006; 23:2635 - 2647
   PubMed Web of Science ®Google Scholar
• Petrakis S, Sklaviadis T. Identification of proteins with high affinity for refolded and native PrP(C). Proteomics 2006;
   PubMedGoogle Scholar
• Fasano C, Campana V, Zurzolo C. Prions: Protein only or something more? Overview of potential prion cofactors. J Mol Neurosci 2006; 29:195 - 214
   PubMed Web of Science ®Google Scholar
• Lee KS, Linden R, Prado MA, Brentani RR, Martins VR. Towards cellular receptors for prions. Rev Med Virol 2003; 13:399 - 408
   PubMed Web of Science ®Google Scholar
• Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, Krasemann S, Deslys JP, Dormont D, Lasmezas CI, Weiss S. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. Embo J 2001; 20:5863 - 5875
   PubMed Web of Science ®Google Scholar
• Hundt C, Peyrin JM, Haik S, Gauczynski S, Leucht C, Rieger R, Riley ML, Deslys JP, Dormont D, Lasmezas CI, Weiss S. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. Embo J 2001; 20:5876 - 5886
   PubMed Web of Science ®Google Scholar
• Gauczynski S, Nikles D, El-Gogo S, Papy-Garcia D, Rey C, Alban S, Barritault D, Lasmezas CI, Weiss S. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 2006; 194:702 - 709
   PubMed Web of Science ®Google Scholar
• Morel E, Andrieu T, Casagrande F, Gauczynski S, Weiss S, Grassi J, Rousset M, Dormont D, Chambaz J. Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am J Pathol 2005; 167:1033 - 1042
   PubMed Web of Science ®Google Scholar
• Leucht C, Simoneau S, Rey C, Vana K, Rieger R, Lasmezas CI, Weiss S. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep 2003; 4:290 - 295
   PubMed Web of Science ®Google Scholar
• Vana K, Weiss S. A Trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells. J Mol Biol 2006; 358:57 - 66
   PubMed Web of Science ®Google Scholar
• Sethi S, Lipford G, Wagner H, Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002; 360:229 - 230
   PubMed Web of Science ®Google Scholar
• Weiss S, Famulok M, Edenhofer F, Wang YH, Jones IM, Groschup M, Winnacker EL. Overexpression of active Syrian golden hamster prion protein PrPc as a glutathione S-transferase fusion in heterologous systems. J Virol 1995; 69:4776 - 4783
   PubMed Web of Science ®Google Scholar
• Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 1997; 3:1383 - 1388
   PubMed Web of Science ®Google Scholar
• Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F. Therapeutic approaches to prion diseases. Clin Lab Med 2003; 23:187 - 208
   PubMed Web of Science ®Google Scholar
• Zuber C, Ludewigs H, Weiss S. Therapeutic approaches targeting the prion receptor LRP/LR. Vet Microbiol 2007; 123:387 - 393
   PubMed Web of Science ®Google Scholar
• Gauczynski S, Hundt C, Leucht C, Weiss S. Interaction of prion proteins with cell surface receptors, molecular chaperones, and other molecules. Adv Protein Chem 2001; 57:229 - 272
   PubMedGoogle Scholar
• Kocisko DA, Caughey B. Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol 2006; 80:1044 - 1046
   PubMed Web of Science ®Google Scholar
• Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, De Luigi A, Limido L, Suardi S, Rossi G, Auvre F, Adjou KT, Sales N, Williams A, Lasmezas C, Deslys JP. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77:8462 - 8469
   PubMed Web of Science ®Google Scholar
• Zuber C, Knackmuss S, Rey C, Reusch U, Rottgen P, Frohlich T, Arnold GJ, Pace C, Mitteregger G, Kretzschmar HA, Little M, Weiss S. Single chain Fv antibodies directed against the 37kDa/67kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008; 45:144 - 151
   PubMed Web of Science ®Google Scholar
• Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources. Ilar J 2005; 46:258 - 268
   PubMed Web of Science ®Google Scholar